Phathom Pharmaceuticals AI Stock Analysis
Want to see PHAT full AI Analyst Report?
Phathom Pharmaceuticals (PHAT) AI Stock Analysis
Phathom Pharmaceuticals
(NASDAQ:PHAT)
The score is held back primarily by weak financial fundamentals (ongoing losses, negative free cash flow, and deeply negative equity) and bearish technicals (price below key moving averages with negative MACD). Offsetting these risks, the latest earnings call was notably constructive with reaffirmed guidance, improving profitability trends, and a stated path to durable positive cash flow in 2027; valuation is difficult to assess due to negative earnings.
Phathom Pharmaceuticals (PHAT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $447.10M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.45M
- Price to Earnings (P/E)
- -5.1
- Beta (1Y)
- 2.16
- Revenue Growth
- 86.75%
- EPS Growth
- 72.98%
- Country
- US
- Employees
- 371
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Phathom Pharmaceuticals Business Overview & Revenue Model
Company Description
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive...
How the Company Makes Money
Phathom makes money primarily by commercializing and selling its VOQUEZNA franchise in the United States. Revenue is generated from product sales to customers (typically wholesalers/distributors and other channel partners) who supply pharmacies and h...
Phathom Pharmaceuticals Earnings Call Summary
The call was strongly positive, supported by 71% year-over-year revenue growth, 14% sequential growth, a second consecutive quarter of operating profitability, positive operating cash flow, more than two million prescriptions filled, reaffirmed full-year guidance, and a substantial cash balance. The main challenges were a Q3 gross margin miss, expected higher Q4 gross-to-net discount, gradual access adoption, and litigation concerning VOQUEZNA's exclusivity, but management remained confident in the commercial trajectory, cash outlook, development pipeline, and long-term GI strategy.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Phathom reiterated full-year 2026 revenue guidance of $310 million-$325 million, expects its full year 2026 gross-to-net discount to come in towards the lower part of its 55%-59% guidance range, continues to anticipate gross margin will be approximately 80%, and maintained cash operating expense guidance, excluding stock-based compensation, of $235 million-$245 million, tracking towards the lower part of that range; it also expects its second consecutive quarter of operating profitability to represent a sustainable pattern going into Q4, including in total for full year 2026 and beyond, and maintained guidance of reaching durable positive cash flow in 2027.
Phathom Pharmaceuticals Financial Statement Overview
Summary
Revenue is growing with very strong gross margins (~83%), but the company remains meaningfully unprofitable (TTM net margin ~-41%) and cash generation is still negative (TTM FCF about -$20.6M). The balance sheet is a major constraint due to deeply negative shareholder equity (about -$348M), despite low latest reported debt.
Income Statement
42NeutralBalance Sheet
28NegativeCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 274.88M | 175.11M | 55.25M | 682.00K | 0 | 0 |
| Gross Profit | 221.77M | 152.51M | 47.28M | 515.00K | -620.00K | -521.00K |
| EBITDA | -19.82M | -152.50M | -261.52M | -159.05M | -169.80M | -136.57M |
| Net Income | -83.00M | -221.25M | -334.33M | -201.59M | -197.72M | -143.88M |
Balance Sheet | ||||||
| Total Assets | 345.02M | 259.15M | 378.32M | 413.84M | 164.81M | 189.43M |
| Cash, Cash Equivalents and Short-Term Investments | 184.56M | 129.97M | 297.26M | 381.39M | 155.38M | 183.26M |
| Total Debt | 167.96M | 211.80M | 201.91M | 139.03M | 97.07M | 91.34M |
| Total Liabilities | 692.66M | 697.32M | 631.90M | 486.60M | 239.62M | 117.28M |
| Stockholders Equity | 0 | -438.17M | -253.58M | -72.76M | -74.81M | 72.16M |
Cash Flow | ||||||
| Free Cash Flow | -21.04M | -167.00M | -266.90M | -139.21M | -147.57M | -148.78M |
| Operating Cash Flow | -20.74M | -166.78M | -266.77M | -137.58M | -146.53M | -148.46M |
| Investing Cash Flow | -302.00K | -229.00K | -135.00K | -1.63M | -1.04M | -328.00K |
| Financing Cash Flow | 70.44M | -288.00K | 182.77M | 367.58M | 120.04M | 44.71M |
Phathom Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHAT, the sentiment is Negative. The current price of 5.30 is below the 20-day moving average (MA) of 5.83, below the 50-day MA of 6.75, and below the 200-day MA of 9.90, indicating a bearish trend. The MACD of -0.35 indicates Negative momentum. The RSI at 37.42 is Neutral, neither overbought nor oversold. The STOCH value of 38.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHAT.
Phathom Pharmaceuticals Risk Analysis
Phathom Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. Phathom Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksPhathom Pharmaceuticals Peers Comparison
Overall Rating
PHAT50Neutral
ARDX49Neutral
ASMB48Neutral
ENTA44Neutral
PALI41Neutral
VNDA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $430.85M | -5.14 | 29.66% | ― | 86.75% | 72.98% | |
| 49Neutral | $799.36M | -13.89 | -35.30% | ― | 17.57% | 4.82% | |
| 48Neutral | $460.74M | 27.30 | -4.40% | ― | 80.18% | 94.20% | |
| 44Neutral | $253.10M | -3.50 | -64.32% | ― | -3.56% | 38.76% | |
| 41Neutral | $168.90M | -4.25 | -35.60% | ― | ― | 94.77% | |
| 39Underperform | $226.76M | -0.81 | -106.94% | ― | 8.11% | -222.50% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | 5.30 | -9.06 | -63.09% | |
| PALI | Palisade Bio, Inc. | 0.94 | -1.40 | -59.74% | |
| VNDA | Vanda Pharmaceuticals | 3.75 | -1.09 | -22.52% | |
| ENTA | Enanta Pharmaceuticals | 8.23 | -3.90 | -32.15% | |
| ARDX | Ardelyx Inc | 3.12 | -2.43 | -43.78% | |
| ASMB | Assembly Biosciences Inc | 22.39 | -14.34 | -39.04% |
Phathom Pharmaceuticals Corporate Events
Phathom Pharmaceuticals Defends VOQUEZNA FDA Exclusivity Rights
NeutralOn October 26, 2026, Phathom Pharmaceuticals reported that the U.S. Food and Drug Administration opened a public docket to gather comments on legal and regulatory issues arising from litigation brought by BDR Pharmaceuticals over the FDA’s rejection...
Phathom Defends VOQUEZNA Exclusivity Amid FDA Lawsuit
NeutralOn October 23, 2026, Phathom Pharmaceuticals reported that BDR Pharmaceuticals International filed a lawsuit against the U.S. Food and Drug Administration and federal defendants, challenging the agency’s alleged refusal to accept an abbreviated new d...
Phathom Starts Phase 3 VOQUEZNA Trial in NERD
PositiveOn September 29, 2026, Phathom Pharmaceuticals began patient screening in its pHalcon-NERD-302 registrational Phase 3 trial of VOQUEZNA tablets as an as-needed regimen for adults with Non-Erosive GERD. The multicenter, randomized, double-blind study...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
